Metabolite targeting: development of a comprehensive targeted metabolomics platform for the assessment of diabetes and its complications

Metabolomics

Volumn 12, Issue 3, 2016, Pages 1-15

  Meiss, Ernst ^a   Werner, Philipp ^a   John, Clara ^a   Scheja, Ludger ^a   Herbach, Nadja ^b   Heeren, Jörg ^a   Fischer, Markus ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Diabetes; Diabetic nephropathy; GIPRdn transgenic mice; Hydrophilic interaction chromatography; LC ESI MS MS; Targeted metabolomics

Indexed keywords

BIOLOGICAL MARKER;

ANALYTICAL PARAMETERS; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ELECTROSPRAY; FEMALE; HYDROPHILIC INTERACTION CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; MOUSE; NONHUMAN; PROTEIN ANALYSIS; SCREENING; VALIDATION STUDY;

EID: 84958049931     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-016-0958-0     Document Type: Article

References (38)

1. Altmaier, E., Ramsay, S. L., Graber, A., Mewes, H.-W., Weinberger, K. M., & Suhre, K. (2008). Bioinformatics analysis of targeted metabolomics—Uncovering old and new tales of diabetic mice under medication. Endocrinology,149, 3478–3489.
2. Bao, Y., et al. (2009). Metabonomic variations in the drug-treated Type 2 diabetes mellitus patients and healthy volunteers. Journal of Proteome Research,8, 1623–1630.
3. Bonnefond, A., & Froguel, P. (2015). Rare and common genetic events in type 2 diabetes: What should biologists know? Cell Metabolism,21, 357–368.
4. Chen, P., & Liu, J. (2007). Metabonomics and diabetes mellitus. Advances in Therapy,24, 1036–1045.
5. Ciapaite, J., Bakker, S. J. L., Heine, R. J., Krab, K., & Westerhoff, H. V. (2007). A systems biology perspective on obesity and Type 2 diabetes. In V. Saks (Ed.), Molecular system bioenergetics: Energy for life (pp. 571–592). Weinheim: Wiley.
6. Connor, S. C., Hansen, M. K., Corner, A., Smith, R. F., & Ryan, T. E. (2010). Integration of metabolomics and transcriptomics data to aid biomarker discovery in type 2 diabetes. Molecular BioSystems,6, 909–921.
7. Demetz, E., et al. (2014). The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metabolism,20, 787–798.
8. FDA. (2001). Food and Drug Administration: Guidance for industry, bioanalytical method validation. Rockville: Department of Health and Human Services.
9. Fiehn, O., & Kind, T. (2007). Metabolite profiling in blood plasma. Methods in Molecular Biology,358, 3–17.
10. Galazis, N., Iacovou, C., Haoula, Z., & Atiomo, W. (2012). Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with polycystic ovary syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology,160, 121–130.
11. Gika, H. G., Theodoridis, G. A., & Wilson, I. D. (2008). Hydrophilic interaction and reversed-phase ultraperformance liquid chromatography TOF-MS for metabonomic analysis of Zucker rat urine. Journal of Separation Science,31, 1598–1608.
12. Godzien, J., et al. (2011). Metabolomic approach with LC-QTOF to study the effect of a nutraceutical treatment on urine of diabetic rats. Journal of Proteome Research,10, 837–844.
13. Herbach, N., Goeke, B., Schneider, M., Hermanns, W., Wolf, E., & Wanke, R. (2005). Overexpression of a dominant negative GIP receptor in transgenic mice results in disturbed postnatal pancreatic islet and beta-cell development. Regulatory Peptides,125, 103–117.
14. Herbach, N., et al. (2009). Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis. American Journal of Physiology Renal Physiology,296, 819–829.
15. Huang, Q., et al. (2011). Method for liver tissue metabolic profiling study and its application in type 2 diabetic rats based on ultra performance liquid chromatography-mass spectrometry. Journal of Chromatography B,879, 961–967.
16. IDF. (2011). International diabetes federation annual report (pp. 1–36). Belgium: Brussel.
17. Ismail, A. A., & Gill, G. V. (1999). The epidemiology of Type 2 diabetes and its current measurement. Baillière’s Best Practice & Research Clinical Endocrinology & Metabolism,13, 197–220.
18. John, C., et al. (2014). A liquid chromatography-tandem mass spectrometry-based method for the simultaneous determination of hydroxy sterols and bile acids. Journal of Chromatography A,1371, 184–195.
19. Kanehisa, M. (2002). The KEGG database. Novartis Found Symp,247, 91–101. discussion 101–103, 119–128, 244–252.
20. Magnusson, M., et al. (2015). Dimethylglycine deficiency and the development of diabetes mellitus. Diabetes,64, 3010–3016.
21. Malecki, M. T. (2005). Genetics of type 2 diabetes mellitus. Diabetes Research and Clinical Practice,68, S10–S21.
22. Ohlson, L.-O., et al. (1988). Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia,31, 798–805.
23. Patti, G. J., Yanes, O., & Siuzdak, G. (2012). Innovation: Metabolomics: The apogee of the omics trilogy. Nature Reviews Molecular Cell Biology,13, 263–269.
24. Preet, A., Karve, T. M., Rizk, N., & Cheema, K. (2012). Metabolomics: Approaches and applications to diabetes research. Journal of Diabetes & Metabolism,S6, 001.
25. Puri, P., et al. (2009). The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology,50, 1827–1838.
26. Rhee, E. P., et al. (2011). Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. The Journal of Clinical Investigation,10, 1–10.
27. Roberts, L. D., & Gerszten, R. E. (2013). Toward new biomarkers of cardiometabolic diseases. Cell Metabolism,18, 43–50.
28. Spagou, K., Tsoukali, H., Raikos, N., Gika, H., Wilson, I. D., & Theodoridis, G. (2010). Hydrophilic interaction chromatography coupled to MS for metabonomic/metabolomic studies. Journal of Separation Science,33, 716–727.
29. Tsutsui, H., et al. (2010). Practical analytical approach for the identification of biomarker candidates in prediabetic state based upon metabonomic study by ultraperformance liquid chromatography coupled to electrospray ionization time-of-flight mass spectrometry. Journal of Proteome Research,9, 3912–3922.
30. Tuomilehto, J., et al. (2001). Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. The New England Journal of Medicine,344, 1343–1350.
31. Wang, T. J., et al. (2011). Metabolite profiles and the risk of developing diabetes. Nature Medicine,17, 448–453.
32. Wenk, M. R. (2005). The emerging field of lipidomics. Nature Reviews Drug Discovery,4, 594–610.
33. Wilson, I. D., et al. (2005). High resolution “Ultra performance” liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. Journal of Proteome Research,4, 591–598.
34. 1H NMR spectroscopy. Analytical and Bioanalytical Chemistry,393, 1657–1668.
35. Yang, J., et al. (2004). Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles. Journal of Chromatography B,813, 53–58.
36. Yuan, K., Kong, H., Guan, Y., Yang, J., & Xu, G. (2007). A GC-based metabonomics investigation of type 2 diabetes by organic acids metabolic profile. Journal of Chromatography B,850, 236–240.
37. Zhao, T., et al. (2012). Intrarenal metabolomics reveals the association of local organic toxins with the progression of diabetic kidney disease. Journal of Pharmaceutical and Biomedical Analysis,60, 32–43.
38. Zhu, C., Liang, Q. L., Hu, P., Wang, Y. M., & Luo, G. A. (2011). Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy. Talanta,85, 1711–1720.